Tango Therapeutics unveiled Phase I/II data for vopimetostat (TNG‑462), an MTA‑cooperative PRMT5 inhibitor, reporting response rates and progression‑free survival in MTAP‑deleted pancreatic ductal adenocarcinoma that exceeded chemotherapy benchmarks. Management announced plans to launch a pivotal study next year in second‑line MTAP‑deleted PDAC based on those results. The dataset prompted a financing and market debate over competitive positioning versus other PRMT5 programs from larger companies, but Tango emphasized the compound’s differentiated activity in MTAP‑deleted tumors and the rationale for a focused, registration‑directed program.